BeiGene Change in Accounts Payable 2014-2024 | ONC
BeiGene annual/quarterly change in accounts payable history and growth rate from 2014 to 2024. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
- BeiGene change in accounts payable for the quarter ending September 30, 2024 was $0.014B, a 56.84% decline year-over-year.
- BeiGene change in accounts payable for the twelve months ending September 30, 2024 was $0.084B, a 395.59% decline year-over-year.
- BeiGene annual change in accounts payable for 2023 was $0.021B, a 593.66% decline from 2022.
- BeiGene annual change in accounts payable for 2022 was $-0.004B, a 121.75% decline from 2021.
- BeiGene annual change in accounts payable for 2021 was $0.02B, a 79.12% decline from 2020.
BeiGene Annual Change in Accounts Payable (Millions of US $) |
2023 |
$21 |
2022 |
$-4 |
2021 |
$20 |
2020 |
$96 |
2019 |
$2 |
2018 |
$23 |
2017 |
$55 |
2016 |
$3 |
2015 |
$6 |
2014 |
$1 |
2013 |
$-1 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|